You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

TEGRETOL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Tegretol patents expire, and what generic alternatives are available?

Tegretol is a drug marketed by Novartis and is included in four NDAs.

The generic ingredient in TEGRETOL is carbamazepine. There are twenty-seven drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the carbamazepine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Tegretol

A generic version of TEGRETOL was approved as carbamazepine by TARO on October 3rd, 1996.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for TEGRETOL?
  • What are the global sales for TEGRETOL?
  • What is Average Wholesale Price for TEGRETOL?
Drug patent expirations by year for TEGRETOL
Drug Prices for TEGRETOL

See drug prices for TEGRETOL

Drug Sales Revenue Trends for TEGRETOL

See drug sales revenues for TEGRETOL

Recent Clinical Trials for TEGRETOL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Arvinas Estrogen Receptor, Inc.Phase 1
PfizerPhase 1
Dr Cipto Mangunkusumo General HospitalPhase 4

See all TEGRETOL clinical trials

US Patents and Regulatory Information for TEGRETOL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis TEGRETOL carbamazepine SUSPENSION;ORAL 018927-001 Dec 18, 1987 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Novartis TEGRETOL-XR carbamazepine TABLET, EXTENDED RELEASE;ORAL 020234-001 Mar 25, 1996 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Novartis TEGRETOL carbamazepine TABLET, CHEWABLE;ORAL 018281-001 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Novartis TEGRETOL carbamazepine TABLET;ORAL 016608-001 Approved Prior to Jan 1, 1982 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Novartis TEGRETOL-XR carbamazepine TABLET, EXTENDED RELEASE;ORAL 020234-003 Mar 25, 1996 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Novartis TEGRETOL-XR carbamazepine TABLET, EXTENDED RELEASE;ORAL 020234-002 Mar 25, 1996 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for TEGRETOL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis TEGRETOL carbamazepine SUSPENSION;ORAL 018927-001 Dec 18, 1987 ⤷  Sign Up ⤷  Sign Up
Novartis TEGRETOL carbamazepine TABLET;ORAL 016608-001 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
Novartis TEGRETOL carbamazepine TABLET, CHEWABLE;ORAL 018281-001 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for TEGRETOL

See the table below for patents covering TEGRETOL around the world.

Country Patent Number Title Estimated Expiration
Philippines 17334 METHOD OF PREVENTING AND TREATING CEREBRAL INSUFFICIENCY ⤷  Sign Up
Australia 8263382 ⤷  Sign Up
Italy 8248224 ⤷  Sign Up
Italy 1147841 PREPARATI FARMACEUTICI PER LA PROFILASSI ED IL TRATTAMENTO DI INSUFFICIENZA DI RENDIMENTO CEREBRALE ⤷  Sign Up
Switzerland 649080 5H-DIBENZ(B,F)AZEPIN-5-CARBOXAMIDE ALS MITTEL ZUR PROPHYLAXE UND BEHANDLUNG VON ZEREBRALER LEISTUNGSINSUFFIZIENZ. ⤷  Sign Up
Belgium 892882 ⤷  Sign Up
Japan S57181013 PHARMACOLOGICAL COMPOSITION FOR PREVENTION AND TREATMENT OF CEREBRAL INSUFFICIENCY ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.